Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in Eosinophilic Esophagitis
NCT00123630Phase 2Completed
- Sponsor
- University of Utah
- Start
- Nov 2005
- Primary completion
- Jan 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in eosinophilic esophagitis (EoE) comparing Omalizumab with Placebo (2 arms). Primary endpoint: Change in Eosinophil Numbers Per High Power Field Proximally and Distally at 16 weeks. Started Nov 2005; status: completed.
02
Drugs
omalizumab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT00123630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00123630.